Hope in the fight against HIV: prophylactic vaccine candidate shows encouraging results

This innovative vaccine candidate called CD40.HIVRI.Env, demonstrated its safety and ability to induce a rapid and durable immune response in the phase I ANRS VRI06 clinical trial .

image : pexels-ron-lach-9893851

This result is the outcome of a collaborative research project between the Vaccine Research Institute (VRI), https://vaccine-research-institute.fr/fr of Inserm, Université Paris-Est Créteil, CHUV Lausanne and researchers in Bordeaux from the BPH-SISTM team https://www.bordeaux-population-health.center/fr/les-equipes/sistm/ of UMS MART https://ums-mart.fr.

This is the first human trial of this vaccine, and the study showed that the vaccine is well tolerated and capable of stimulating both a humoral and cellular immune response against HIV.

The vaccine features an innovative approach that targets dendritic cells, which play a key role in triggering protective immune responses.

Specialized in methodology, coordination and data science of vaccine clinical trials, the Bordeaux teams SISTM and MART have ensured these key elements of the successful conduct of the trial.

The detailed results of this study have been published in eClinical Medicine in October 2024.

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
Yves Levy,Christiane Moog,Aurélie Wiedemann,Odile Launay,Fabio Candotti,Lucile Hardel,Mélany Durand,Véronique Rieux,Alpha Diallo,Christine Lacabaratz,Sylvain Cardinaud,Sandra Zurawski,Gerard Zurawski,Georgia D. Tomaras,Song Ding,Mireille Centlivre,Rodolphe Thiebaut,Giuseppe Pantaleo,Jean-Daniel Lelièvre,Laura Richertthe ANRS VRI06 Study Group

Read the  press release